Raloxifene

Estrogen Agonist/Antagonist — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Raloxifene is an ofp drug in the Estrogen Agonist/Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Selective Estrogen Receptor Modulators. DrugCentral lists 47 molecular targets, including Esr1, ESR1 and EBP. Recorded indications include Postmenopausal osteoporosis and Prevention of Breast Carcinoma.

• Approval status: ofp (first approved 1997 by the FDA).
• Drug class: Estrogen Agonist/Antagonist.
• Mechanism of action: Selective Estrogen Receptor Modulators.
• Molecular targets: Esr1, ESR1, EBP and Esr1|Esr2 (47 listed in DrugCentral).
• Indications: Postmenopausal osteoporosis and Prevention of Breast Carcinoma.
• ATC code: G03XC01 (Selective estrogen receptor modulators).
• Molecular formula: C28H27NO4S; molecular weight 473.59 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Postmenopausal osteoporosis
• Prevention of Breast Carcinoma

Off-label uses (1)

• Prevention of Glucocorticoid-Induced Osteoporosis

Contraindications (19)

• Atrial fibrillation
• Breastfeeding (mother)
• Cardiovascular event risk
• Cerebrovascular accident
• Chronic heart failure
• Deep venous thrombosis
• Disease of liver
• Disorder of coronary artery
• Hypertensive disorder
• Hypertriglyceridemia
• Impaired renal function disorder
• Lupus anticoagulant disorder
• Pregnancy, function
• Pulmonary thromboembolism
• Smokes tobacco daily
• Thrombophilia
• Thrombophlebitis
• Thrombosis of retinal vein
• Transient ischemic attack

Mechanism & targets

• Mechanism of action (MoA): Selective Estrogen Receptor Modulators
• Established pharmacologic class: Estrogen Agonist/Antagonist

Molecular targets (47)

Target	Gene	Action	Activity
Estrogen receptor	Esr1	unknown	Ki 9.43
Estrogen receptor	ESR1	antagonist	IC50 9.40
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	EBP	unknown	Ki 9.00
Estrogen receptor	Esr1|Esr2	unknown	IC50 8.73
Estrogen receptor beta	Esr2	unknown	Ki 8.56
Aldehyde oxidase	AOX1	unknown	IC50 8.54
Interleukin-6	IL6	unknown	IC50 8.05
Estrogen receptor beta	ESR2	modulator	EC50 8.00
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 7.42
C-8 sterol isomerase	ERG2	unknown	Ki 7.18
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 7.16
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.97
Membrane-associated progesterone receptor component 1	Pgrmc1	unknown	Ki 6.62
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 6.55
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 6.52
G-protein coupled estrogen receptor 1	GPER1	unknown	EC50 6.50
D(2) dopamine receptor	DRD2	unknown	Ki 6.41
Acetylcholinesterase	ACHE	unknown	IC50 6.40
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 6.38
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 6.32

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1998-08-05	EMA	—	ELI LILLY NEDERLAND B.V.
1997-12-09	FDA	—	LILLY	Yes

ATC classification

ATC code	Therapeutic hierarchy
G03XC01	GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › Selective estrogen receptor modulators

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: ESR1, ESR2

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Breast cancer	322.5
Endometrial cancer	300.3
Bone density decreased	207.7
Femur fracture	175.2
Deep vein thrombosis	168.9
Retinal vein thrombosis	167.3
Fracture	155.4
Pulmonary embolism	123.9
Spinal compression fracture	119.3
Fall	118.9
Body height decreased	117.7
Hip fracture	110.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Raloxifene is on its molecule page.

• Molecular formula: C₂₈H₂₇NO₄S
• Molecular weight: 473.59 g/mol
• CAS number: 84449-90-1
• InChIKey: GZUITABIAKMVPG-UHFFFAOYSA-N
• PubChem CID: 5035

OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Raloxifene used for?

DrugCentral lists the following indications for Raloxifene: Postmenopausal osteoporosis and Prevention of Breast Carcinoma.

How does Raloxifene work?

Raloxifene is classified as Selective Estrogen Receptor Modulators; its molecular targets in DrugCentral include Esr1, ESR1 (antagonist), EBP and Esr1|Esr2.

When was Raloxifene first approved?

Raloxifene was first approved by the FDA in 1997.

What drug class does Raloxifene belong to?

Raloxifene is in the Estrogen Agonist/Antagonist class.

What is the chemical formula of Raloxifene?

Raloxifene has the molecular formula C28H27NO4S and a molecular weight of 473.59 g/mol.

Sources

• DrugCentral drug card 2351 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1116 — compound record and bioactivity
• PubChem CID 5035 — chemical identifiers
• DrugBank DB00481 — drug record
• FDA UNII YX9162EO3I — substance identity
• DailyMed: FDA labels for Raloxifene — current prescribing information (label search)
• UniProt P03372 (ESR1) — target protein
• UniProt Q15125 (EBP) — target protein
• UniProt Q06278 (AOX1) — target protein
• UniProt P05231 (IL6) — target protein
• UniProt Q92731 (ESR2) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.